Why Amgen Stock Is Getting Hit by a Novartis Trial Setback
Why Amgen Stock Is Getting Hit by a Novartis Trial Setback Barron's
Covered in this story
What has happened since
- Amgen is up 5.1% since this was published, 29 days ago.
- Novartis is up 7.4% since this was published, 29 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Amgen
- Cantor Fitzgerald: $403 → $400 by Oct 2027 · Neutral via Investing.com
- Scotiabank: $403 → $500 by Oct 2027 via AD HOC NEWS
- Scotiabank: $424 → $500 by Sep 2027 · Sector Outperform via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 49 stories mentioning Amgen, the earliest published 14 Jul 2026.
Summary aggregated from Barron's's public RSS feed. The full reporting belongs to Barron's — please read it on their site.